Celltrion’s Remsima wins U.S. original drug substance patent conflict
On a summary judgement filed by Celltrion over the Remicade’s substance patent(U.S. Patent No. 6,284,471, hereinafter referring to ‘471 substance patent’), the United States District Court for the District of Massachusetts has issued a ruling that the ‘471 substance patent’ is invalid on the 17th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
